Abstract P5-21-20: Integrating comprehensive genomic profiling with treatment decisions – Experience gained while treating 139 advanced breast carcinomas

Autor: R Mahtani, LM Gay, J Chung, R Hartmaier, E Sokol, JA Elvin, S Daniel, S Ramkissoon, E Severson, J Suh, J-A Vergilio, PJ Stephens, JS Ross

Publikováno v: Cancer Research. 78:P5-21

Background: Comprehensive Genomic Profiling (CGP) using next-generation sequencing (NGS) technology can provide insight into potentially clinically relevant genomic alterations (CRGA) within a patient's breast cancer. For example, HER2 amplification

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3e99220aa225a68dcb4987933ba04950
https://doi.org/10.1158/1538-7445.sabcs17-p5-21-20

Abstract P1-05-08: Comprehensive genomic profiling of 8,654 breast carcinoma reveals therapeutically targetable molecular subtypes beyond those defined by hormone-receptor expression

Autor: JS Ross, LM Gay, JA Elvin, J Suh, J-A Vergilio, S Ramkissoon, A Schrock, S Ali, VA Miller, PJ Stephens

Publikováno v: Cancer Research. 77:P1-05

Background: Breast carcinomas (BC) are commonly classified into 4 subtypes based on hormone receptor expression: basal, luminal A, luminal B, and HER2 overexpressed. Comprehensive genomic profiling (CGP) reveals targetable genomic alterations (GA) ac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d61bdfc0debeec83178459226bcb3ff9
https://doi.org/10.1158/1538-7445.sabcs16-p1-05-08

Pan-tumor validation of a NGS fraction-based MSI analysis as a predictor of response to Pembrolizumab.

Autor: Lin DI; Foundation Medicine, Inc., Boston, MA, USA. dlin@foundationmedicine.com., Quintanilha JCF; Foundation Medicine, Inc., Boston, MA, USA., Danziger N; Foundation Medicine, Inc., Boston, MA, USA., Lang L; Merck & Co., Inc., Rahway, NJ, USA., Levitan D; Merck & Co., Inc., Rahway, NJ, USA., Hayne C; Beth Israel Deaconess Medical Center, Boston, MA, USA., Hiemenz MC; Foundation Medicine, Inc., Boston, MA, USA., Smith DL; Foundation Medicine, Inc., Boston, MA, USA., Albacker LA; Foundation Medicine, Inc., Boston, MA, USA., Leibowitz J; Foundation Medicine, Inc., Boston, MA, USA., Mata DA; Foundation Medicine, Inc., Boston, MA, USA., Decker B; Foundation Medicine, Inc., Boston, MA, USA., Lakis S; Foundation Medicine GmbH, Penzberg, Germany., Patel NR; Foundation Medicine, Inc., Boston, MA, USA., Graf RP; Foundation Medicine, Inc., Boston, MA, USA., Elvin JA; Foundation Medicine, Inc., Boston, MA, USA., Ross JS; Foundation Medicine, Inc., Boston, MA, USA., Pattani V; Foundation Medicine, Inc., Boston, MA, USA., Huang RSP; Foundation Medicine, Inc., Boston, MA, USA., Wehn AK; Merck & Co., Inc., Rahway, NJ, USA.

Publikováno v: NPJ precision oncology [NPJ Precis Oncol] 2024 Sep 14; Vol. 8 (1), pp. 204. Date of Electronic Publication: 2024 Sep 14.

Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.

Autor: Mata DA; Foundation Medicine, Inc., Cambridge, MA, USA., Lee JK; Foundation Medicine, Inc., Cambridge, MA, USA., Shanmugam V; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Marcus CB; Foundation Medicine, Inc., Cambridge, MA, USA., Schrock AB; Foundation Medicine, Inc., Cambridge, MA, USA., Williams EA; Foundation Medicine, Inc., Cambridge, MA, USA.; Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL, USA., Ritterhouse LL; Foundation Medicine, Inc., Cambridge, MA, USA., Hickman RA; Foundation Medicine, Inc., Cambridge, MA, USA., Janovitz T; Foundation Medicine, Inc., Cambridge, MA, USA., Patel NR; Foundation Medicine, Inc., Morrisville, NC, USA., Kroger BR; Division of Hematology/Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA., Ross JS; Foundation Medicine, Inc., Cambridge, MA, USA.; Departments of Pathology, Urology, and Medicine (Oncology), State University of New York Upstate Medical University, Syracuse, New York, USA., Mirza KM; Department of Pathology, Michigan Medicine, Ann Arbor, MI, USA., Oxnard GR; Foundation Medicine, Inc., Cambridge, MA, USA., Vergilio JA; Foundation Medicine, Inc., Cambridge, MA, USA., Elvin JA; Foundation Medicine, Inc., Cambridge, MA, USA., Benhamida JK; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Decker B; Foundation Medicine, Inc., Cambridge, MA, USA., Xu ML; Department of Pathology, Yale New-Haven Hospital, Yale School of Medicine, New Haven, CT, USA.

Publikováno v: Histopathology [Histopathology] 2024 Jun; Vol. 84 (7), pp. 1224-1237. Date of Electronic Publication: 2024 Feb 29.

Understanding the Landscape of Clinically Available Molecular Testing.

Autor: Elvin JA; Pathology and Diagnostic Medicine, Foundation Medicine, Inc 400 Summer Street, Boston, MA 02210, USA. Electronic address: jelvin@foundationmedicine.com.

Publikováno v: Surgical oncology clinics of North America [Surg Oncol Clin N Am] 2024 Apr; Vol. 33 (2), pp. 217-230. Date of Electronic Publication: 2024 Jan 29.